Abstract 1152P
Background
Therapy with ICIs have been successful with long-term survival benefits for some CMM patients. However, ICIs may also cause irAEs which could be serious and demand the prescription of GC. The combination of ICIs improves treatment efficacy but increases the risk for irAEs. The impact of GC treated irAE (GC-irAE) on efficacy of ICIs is not fully understood and biomarkers assessing the risk for irAE requiring GC treatment are not available. We studied a cohort of patients with metastatic CMM treated with ICI to evaluate if GC-irAE impact clinical outcome. We also investigated whether inflammation proteins in baseline plasma samples may predict the development of GC-irAE.
Methods
This is a cohort study performed at Karolinska University Hospital in Sweden including 98 subjects with advanced CMM (M1a-d), who received anti-PD1 alone (n=88), anti-PD1+ epacadostat (clinical trial, n=3) or ipilimumab + nivolumab (n=8) as 1st line therapy in most cases (85%). Clinical data regarding the use of GC to treat irAE were collected retrospectively. If GC-irAE occurred, the type of irAE was assembled. Baseline plasma samples from 58 of the 98 patients were analyzed utilizing the OLINK inflammation protein panel platform.
Results
In the whole cohort 65% were male and median age was 70 years. The median PFS and OS for the whole cohort were 12 and 38 months, respectively. Of 98 patients 44% developed GC-irAE. The most common GC-irAE were hypophysitis (11%), dematitis (7%), colitis (7%) and pneumonitis (6%). The median time to GC treatment start after ICI therapy was 146 days. The median PFS and OS for GC-irAE vs patients without GC-irAE were 24 and 73 months vs 5 and 18 months, respectively. Patients developing hypophysitis had a longer OS compared to other patients. High baseline levels of IL8 and S100A12 were associated with worse OS and high levels of DNER was associated with better OS and with risk of developing hypophysitis.
Conclusions
Patients developing a GC-irAE had significantly increased PFS and OS compared to the other patients. Further studies on potential biomarkers for risk of developing hypophysitis are warranted to timely avoid serious complications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University Hospital, Region Stockholm.
Funding
Cancerfonden, Radiumhemmets Forskningsfond and Region Stockholm (ALF).
Disclosure
F. Costa Svedman: Financial Interests, Institutional, Speaker, Consultant, Advisor, participated in an expert panel, honorary payment to the clinic: Pfizer; Financial Interests, Institutional, Speaker, Consultant, Advisor, Travel financing for participating in a preceptorship and reporting. Payment went to the clinic: Merck; Financial Interests, Institutional, Speaker, Consultant, Advisor, I do not receive any payment personally: BMS; Other, Institutional, Local PI, I do not receive any payment personally: Eisai, Merck, Idera; Other, Institutional, Coordinating PI, I do not receive any payment personally: Merck. A. Chatzidionysiou: Financial Interests, Institutional, Financially compensated role, Consultant fees went to Institutional Research: Eli Lilly, AbbVie, Pfizer; Other, Institutional, Coordinating PI: Janssen, Pfizer. A. Månsson-Broberg: Financial Interests, Institutional, Funding, Research funding: Amgen; Financial Interests, Institutional, Speaker, Consultant, Advisor: Orion Pharma, BMS; Other, Institutional, Local PI: Cardio3BioSciences. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13